Stocksigma LogoStocksigma Logo

Jagsonpal Pharmaceuticals Reports Q2 FY27 Results and Strategic Hospital Segment Entry

Jagsonpal Pharmaceuticals reported standalone revenue from operations of ₹813.75m for the quarter ended 30th Sep'26, up 9.28% YoY, with net profit at

Jagsonpal Pharmaceuticals Reports Q2 FY27 Results and Strategic Hospital Segment Entry

Jagsonpal Pharmaceuticals Ltd · Outcome · 28 Oct 2026, 11:39 pm

Jagsonpal Pharmaceuticals Reports Q2 FY27 Results and Strategic Hospital Segment Entry Jagsonpal Pharmaceuticals reported standalone revenue from operations of ₹813.75m for the quarter ended 30th Sep'26, up 9.28% YoY, with net profit at ₹125.90m versus ₹125.74m in the previous year quarter. Consolidated revenue stood at ₹963.71m with net profit at ₹122.87m. The company completed an 85% equity acquisition in Aequitas Healthcare for ₹208m effective 1st Jul'26 to enter the hospital segment, incurring ₹2.35m in exceptional deal costs. It also signed a slump sale agreement on 23rd Sep'26 to acquire Group Pharmaceuticals' Wellness Portfolio.

Original exchange filing (PDF)

More announcements from Jagsonpal Pharmaceuticals Ltd

All Jagsonpal Pharmaceuticals Ltd announcements